LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that J. Thomas Megerian, M.D., Ph.D., executive director for clinical development at EPIX, is scheduled to participate in a session entitled, “From In Silico to Patient; A Case Study in Expedited Drug Development for Alzheimer’s Disease” at the First International Neuron to Synapse 2008 Meeting On Neurobiology to Neurodegenerative Diseases and Therapeutics at Harvard Medical School in Boston on Tuesday, May 27, 2008 at 3:40 p.m. (ET).
